Clinical Trial Update: A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of ocrelizumab in relapsing-remitting multiple sclerosis; the trial is completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED | Results posted: 2017-05-11